[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer

Launched by CITY OF HOPE MEDICAL CENTER · Aug 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a special imaging technique called \[18F\]-rhPSMA PET-CT to help doctors see prostate cancer cells more clearly. The \[18F\]-rhPSMA is a small radioactive substance that targets prostate cancer cells, making them visible on scans. This trial aims to compare the standard imaging method with a new system called the RefleXion Medical Radiotherapy System (RMRS), which uses real-time imaging to guide targeted radiation therapy. By gathering information from this study, researchers hope to enhance the quality of imaging and improve treatment for prostate cancer patients.

To participate in this trial, men aged 21 and older who have already undergone the standard \[18F\]-rhPSMA PET-CT scan and have identifiable cancerous lesions may qualify. Participants will need to provide consent and can expect to have a follow-up scan using the RMRS on the same day. It's important to note that individuals with certain psychiatric or substance abuse disorders or those exceeding a weight limit of 450 pounds cannot join the study. This research could lead to better imaging techniques and more effective radiation therapy plans for patients with prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Documented informed consent of the participant and/or legally authorized representative
• • Age: ≥ 21 years
• • Patients with SOC \[18F\]-RhPSMA PET-CT in whom a PET avid lesion is identified
• • Able to get same day X1 RMRS PET
• Exclusion Criteria:
• • Known psychiatric or substance abuse disorder that would interfere with conduct of the study
• • Patient weight exceeding the weight limit (450 pounds) outlined per X1 RMRS specifications sheet